15%
Extra Off On Every Report

Pharmaceuticals

 

Upcoming

Vaccines are biotic compositions. They are basically formulated from living beings that increase the resistance against a specific illness. Vaccinations that help in avoiding the occurrence of specific diseases are known as prophylactic vaccines and in other instance, the vaccines that are helpful in treating the disease are called therapeutic vaccines. A vaccine is generally produced by using a weakened or murdered type of the sickness causing microorganism. The agent penetrates the immune system of body to perceive the agent as a risk, crush it, and to moreover identify and annihilate any of the microorganisms related with that particular operator that it might affect in near future. Vaccinations plays vital role in maintaining the supportable people’s health across the globe; therefore, they are used to prevent various regional disease. Due to the rise in cases of both viral and bacterial contagious diseases the demand for vaccinations has increased over the last few years. Vaccines are basically regulated to the different people of different age groups. Vaccinations supports their immune system throughout their life and provides safety against distinct types of infectious diseases.

However, shipping of vaccines and cost related with storage and restricted compensation coverage are forecasted to confine the global viral vaccines market during the forecast period. Furthermore, rigorous governmental rules for the support of biotic products is likely to hinder the growth of the global viral vaccine market in the upcoming years. The world-wide viral vaccines market is determined by the increase in frequency of infective diseases, as they are considered to be the finest way to avoid such diseases. The influence of the dynamic factors is moreover to surpass the restraints. Furthermore, development of new markets and rise in adoption of combination of vaccines in preventing strategies by government are responsible for the new and growing opportunities in the future.

Majorly, there are four types of primary vaccines. Which are live inactivated vaccines, attenuated vaccines, toxoid vaccines and conjugate vaccines. Viral vaccines are consists of killed or attenuated virus or their product that can trigger the immune system to produce antibodies in contradiction of them. Depending upon the indications, the vaccines can be further divided into pneumococcal disease; influenza; human papilloma virus; rotavirus;  meningococcal disease; varicella; diphtheria, measles, and tetanus (DTP), polio; hepatitis; pertussis, mumps, and rubella (MMR); and other indications. Considering the end use, it is categorized into adult vaccines, pediatric vaccines and traveler vaccines. Further, viral vaccine can be segmented into technology, indication, end use and region.

The major players dominating the global viral vaccine market are PaxVax Corporation., Gritstone Oncology, Bharat Biotech, Novavax, Inc., VBI Vaccines Inc., Dynavax Technologies Corporation, Bavarian Nordic, Biology Ltd.  Gamma Vaccines Pty Limited, Prokarium, Sinovac Biotech Ltd., Immunomic Therapeutics, Inc,

20
Jul
18
The oral contraceptive pills market is expected to reach USD 24.0 Billion by 2025 from USD 13.8 Billion in 2016 at a CAGR of 6.4%. Oral contraceptive pills are drugs that prevent pregnancy upon its consumption in a stipulated time during the menstrual cycle. The drug component--estrogen and progesterone hormones prevent the ovary from releasing egg for fertilization.

Increase in favorable government policies and rise in awareness among consumers regarding unintended pregnancies are set to drive the market over the forecast period. Increasing population and various awareness initiatives that witness a good participation of women, adolescents, and young people, at all stages of planning, implementation, and evaluation helps in curbing the population as well as creates a demand for contraceptives resulting in increased sales.

Women are increasingly using oral contraceptive pills to prevent unwanted pregnancies

Women are increasingly postponing motherhood in order to prioritize their careers and maintain their job safety. Besides, increase in the number of unstable relationships and high costs involved in raising a child are several factors that are increasingly causing women to postpone pregnancy, thereby fueling this industry. In the developing countries, the supply of contraceptives is lesser than the increasing demand of these drugs. Particularly in Africa, diseases like HIV etc. have made usage of drugs that prevent pregnancy essential for women. Thus, net sales of contraceptive products in developing countries are anticipated to increase the market growth over the forecast period. However, concerns regarding the side effects of products can negatively impact the product demand in future.

                         
 
Combination oral contraceptive pills hold the largest share in the product segment of the market

The oral contraceptive pills market has been bifurcated into combination, progestin-only and others on the basis of product types. Combination pills are sub divided into monophasic pills, triphasic pills and others. The combination oral contraceptive pills pills in this segment is projected to register the highest growth rate over the course of the forecast period which can be attributed to easy availability, preference of consumers and higher efficiency in preventing pregnancies.

Generic oral contraceptive pills have witnessed widespread adoption and are the fastest growing segment in this industry

Categorically, the market is segregated into generic oral contraceptive pills and branded pills. The generic oral contraceptive pills lead this segment and are projected to record the fastest growth rate over the forecast period which can be attributed to ease of use and low prices leading to widespread adoption.

North America witnessed the fastest growing Oral contraceptive pills Pill market due to favorable reimbursement policies in U.S.

Geographically, the market has been segregated into five major regions: North America, Europe, Asia Pacific, Middle East and Africa and Latin America. The North America region accounts for the highest unintended pregnancies in the region and thus ruled the oral contraceptive pills market. Based on a study conducted by The Centers for Disease Control and Prevention (CDC), 37% of the total pregnancies in the U.S during 2006 to 2010, were unintended. To this end, the governments of North American countries are encouraging women to opt for modern and more effective contraceptive options. 

Obamacare, the enforcement of the Affordable Care Act and various other awareness programs by non-profit organizations have brought forth favorable reimbursement policies and thus, increased the sale of oral contraceptive pills in the region. The Asia Pacific region is also viewed as one of the most upcoming and attractive market for oral contraceptive pills in the course of the forecast period. This can be attributed to the massive population and rise in steady economic development in countries such as India, China, Singapore, Australia, and Philippines.

The key players in the global oral contraceptive pills market include Merck & Co., Inc., Reckitt Benckiser, Teva Pharmaceutical Industries Ltd., Bayer AG, Janssen Global Services, LLC, Allergan,plc (Actavis), Mankind Pharma Ltd., Actavis, Inc., Cooper Surgical, Pfizer, Inc., Piramal Enterprises Ltd., and Church & Dwight Co.

21
Jul
18
The Active Pharmaceutical Ingredient market is expected to reach USD 272.63 Billion by 2025 from USD 157.26 Billion in 2016 at a CAGR of 6.4%. Active Pharmaceutical Ingredient (API) is biological or chemical products in the drug that actively works in treating the condition or disease. A single drug may contain one or more APIs and create a reaction or response to the ailment/condition. Based on the intensity of reaction APIs are capable of, the dosage of a medicine is prescribed and have a wide range of function including treatment or cure of the various ailments, diagnosis of a disease/condition or prevention.

The rising application of specialty medicines, increased demand of generic and branded drugs has increased the overall spending of the medicine market, thereby contributing to the growth of medicine market. However, particularly for the API market, availability of affordable labor costs and abundant raw material are the critical factors responsible for the substantial growth in the API market. The government’s favorable tax policies and supportive regulatory policies also encourage establishment of API manufacturing plants and are therefore contributing in fueling the growth of API market.
Consumption of non-controlled drugs by an extremely large patient population base is also a key factor leading to the increased sales of APIs. However, manufacturers of active pharmaceutical ingredient require long-term contracts with western drug manufacturers and application of sophisticated technologies in order to optimize of economies of scale which acts as a constraint for the API market.

              
 
Based on manufacturing process, the market is segmented into captive manufacturing and contract manufacturing. Contract Manufacturing holds substantial share in the API market as not all pharmaceutical companies are integrated with a separate unit for formulation of active drug ingredients leading to increased outsourcing of API molecules.

Types of active pharmaceutical ingredients described in the global market include synthetic chemical API and biological API. The Synthetic chemical API dominates the API market due to their extensive availability. However, rising demand for biosimilar and protein-based therapeutics are estimated to contribute toward lucrative growth of biotech APIs market. On the basis of drug type, the market is bifurcated into branded prescription drugs, generic prescription drugs, OTC prescription drugs. The branded prescription drugs are leading this segment due to their higher demand in developing countries.

The global therapeutics market encompasses sub sections such as cardiovascular disorders, oncology, metabolic disorders, neurological disorders, musculoskeletal disorders, NSAIDs and other therapeutic uses. Cardiovascular diseases hold the largest share in the therapeutics segment of API market due to high prevalence of heart diseases. However, the oncology segment is projected to increase its hold on the market owing to high number of products waiting for market approval.

Geographically, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa and Latin America. The North American Region dominated the overall API market over the forecast period owing to the sophisticated R&D techniques and ample expenditure, favorable government policies for usage of generic drugs and advanced technologies.in the drug manufacturing field. Asia Pacific is expected to follow North American market due to increased demand and availability of affordable labor.

Major players profiled in the report include Sandoz (Novartis AG), Lonza Group, Pfizer, Inc., Boehringer Ingelheim Group, WuXi Apptec, BASF SE, Cambrex Corporation, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Allergan plc and Mylan, Inc.


Upcoming

Small molecule targeted cancer therapies are designed to block the growth of cancerous cells in the body. Usually, rapidly dividing cancer cells’ cell division is inhibited by conventional cytotoxic medications and chemotherapies. But, the mechanism of action of small molecule targeted therapies have an added advantage of destroying cancerous cells with high precision and relatively fewer side effects. Treatment of various cancers such as breast cancer, melanoma, multiple myeloma, prostate cancer lymphoma, and other cancers can be done via small molecule targeted cancer therapy.

One of the essential drivers of this market is the high adoption rates of this therapy. Glaxo Smith Kline sponsored a program where International Society of Nurse in Cancer Care’s nurses led a Small Molecule Chemotherapy Patient Education Program that was aimed at adhering self-care capacity of patients going through small molecule therapy. Thus, such supportive initiatives enhance the adoption rate of this therapy thereby fueling the market growth.

A report by International Agency for Research on Cancer (IARC) suggests that a total of 13 million new cancer cases are diagnosed worldwide whereas the World Cancer Report provides the rate of new cancer cases, which is expected to increase by 50% to 15 million by 2020. Thus increasing incidence of cancer is projected to escalate the market growth. Additionally, patent expiration of essential drugs is expected to act as an opportunity for manufacturers of target release drugs. For instance, patent of Glivec drug manufactured by Novartis is due to expire, thereby opening new avenues for small molecule targeted cancer therapy market.

Among various treatment methods, small molecules targeted therapy is preferred owing to convenience in administration and lesser costs. For instance, treatment via small molecules can be developed to target any cell location, unlike monoclonal antibodies treatment methods. MAbs are also inefficient in delivering drugs to the brain tissues as the blood–brain barrier prohibits entry of molecules larger in weight, thus small molecules have an added advantage as they can be delivered intra-tumorally. Moreover, FDA claims that the half-life of mAbs like cetuximab (3.1-7.8 days) is much longer than certain small-molecule operatives like gefitinib (48 hours). Furthermore, small molecules are capable of penetrating the interstices of a tumor and target intra-cellular signaling protein. Their identification and purity can be ensured by various scientific methods making them easy to reproduce and they can also be administered orally unlike antibodies that are administered intravenously. It is estimated that further research over small molecules might prove to be an alternative to the antibodies in cancer immunotherapy.

Small molecule targeted cancer therapy market is classified as small molecules, small molecule drug conjugates, and monoclonal antibodies. The small molecules segment is further classified into small molecule tyrosine kinase inhibitor (imatinib), small molecule cyclin-dependent kinase inhibitor (seliciclib), and small molecule proteasome inhibitor (bortezomib). Based on monoclonal antibodies, the market can be further segmented into humanized monoclonal antibody (with a circulatory system target), fully human antibody (with an immune system target), chimeric monoclonal antibody (with a tumor target), and humanized monoclonal antibody (with a circulatory system target). Geographically, North America, Europe, and Asia Pacific are expected to experience dominance of this market.

The North American region is anticipated to dominate the market owing to the increasing prevalence of cancer. In a report, the National Institute of Health estimates that in U.S. alone, the medical expenditure for cancer is expected to cross $150 billion by 2020. Thus, growing incidence of cancer and lesser side effects of small molecule targeted therapy are expected to propel the market growth in North America further over the forecast period.

Key players of the small molecule targeted cancer therapy market are Boehringer Ingelheim GmbH, Abbott Laboratories, Cytokinetics Inc., Bayer HealthCare AG, OncoGenex Pharmaceuticals Inc., Hospira Inc., and GlaxoSmithKline PLC.


Upcoming

The World Health Organization defines Pharmacovigilance (Pharmacovigilance) as -“the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem”. The aim of pharmacovigilance is to enhance patient safety as well as care with respect to the use of medicines and to support public health programs by providing balanced and trustworthy information for the effective assessment of the risk-benefit profile of medicines.

There has been a considerable rise in the number of drugs made available to healthcare consumers owing to increased pharmaceuticals consumption for various diseases in non-hospital set ups. The need for novel therapeutics development via extensive clinical trials has heightened and is expected to augment the growth of this market.

Various crucial pharmaceutical companies have initiated extensive R&D in order to develop innovative therapeutic molecules thereby increasing the rate of drug development. Drug manufacturers are concentrating on remodeling of their product development processes so as to tend to the needs of patients across globe. Furthermore, in order to minimize operational expenses and cut costs, many leading pharmaceutical companies in the developed countries are outsourcing pharmacovigilance service. For instance, Accenture and BioCelebrate entered into a collaborative agreement for developing a platform for analyzing and aggregating clinical information in April, 2017. This information enhances R&D capabilities as it records improvements in drug developing efficiency and ensures significantly lower costs for pharmacovigilance services as companies such as TCS, Wipro and Cognizant in developing region are more affordable. Furthermore, while experts present in the outsourced companies take care of pharmacovigilance services, the manufacturers can focus on their primary objectives. This factor is anticipated to act as an opportunity for contact research organizations in many developing countries and contribute in gaining more revenue share.

Another factor driving the global pharmacovigilance market is the rise in awareness about drug safety and efficacy around the globe and the considerable demand for adopting safe medicinal practices. The market has gained momentum in developing as well as emerging economies due to the increasing governmental support in opening centers dedicated to pharmacovigilance. Furthermore, the government agencies have set up stringent laws for post-market monitoring mechanisms in order to ensure effective drug regulation system. This is another notable aspect anticipated to catalyze the market growth. However, concerns over safety of patient data due to increased cases of data theft and lack of technologically-advanced infrastructure that can support pharmacovigillance infrastructure are expected to act as key constraints for this market.

The global pharmacovigilance market is segmented on the basis of Preclinical Studies, types of methods,types of services and region. On the basis of preclinical studies, the market is bifurcated into Phase I, Phase II, Phase III and Phase IV or Post Marketing Surveillance. Based on type of method, the market is classified into Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining. The type of service segment is further divided into In-house and Contract Outsourcing. Geographically, the market is segregated into North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

The North American region holds the major share in the global pharmacovogillance market owing to technological advancements in the field of healthcare, increasing mortality rates caused by adverse drug reactions (ADR) and heightened awareness among patients about the safety and efficacy of a drug. The Asia Pacific region is also anticipated to register fast growth in the pharmacovigilance market owing to favorable government initiatives for the betterment of adverse drug reaction monitoring, thereby fueling the uptake.

Some of the leading companies in the global pharmacovigillance market Covance Inc., Bristol-Myers Squibb, Cognizant Technology Solutions, Pfizer, Inc., Novartis International AG, Accenture Plc, Wipro Limited, GlaxoSmithKline plc, inVentiv Health, Inc., and F. Hoffmann-La Roche Ltd.


Upcoming

Bone glue is a revolutionary product that can glue broken bones back together and gradually get replaced with bone over time. Its registered name is ‘Tetranite’ and it is made artificially in the lab. Bone glue is inspired from its natural alternative present in barnacles. Scientists and manufacturers involved in the development of innovative bone glues are concentrated on developing multipurpose glue that can be utilized for a large number of applications.

Apart from its application in medicine, bone glue is anticipated to be utilized in pharmaceutical, veterinary and sanitary preparations; dental wax; dietetic substances that can be used medically, fungicides, preparations for destroying vermin; baby foods; disinfectants; wound dressing materials, plasters, teeth stopping material and herbicides. The major players in this market are focused on the introducing novel products to capitalize on various opportunities in the global bone glue market.

One of the essential drivers of this market is bone glue’s revolutionary role in reversing osteoporosis, the crippling bone disease that affects over 200 million people worldwide. New experiments held on the International Space Station by NASA suggest that bone glue could stimulate the production of new bone that can adhere to both metal and bone. Bone glue’s effect during various animal studies showed that it is extremely safe and biocompatible during the bone healing process. Since it can be gradually resorbed by the body and replaced by bone, it can have extensive applications in broken bone fixing, stabilizing metal orthopedic implants and enhancing the structure of bone. These applications can help in the treatment of many bone related diseases which is estimated to fuel its market growth.

Another factor that is estimated to propel the growth of this market is bone glue’s application in repairing bone loss in astronauts who are on long-duration spaceflights. Moreover, the rise in the number of surgical procedures that may require bone glue in large volume is also estimated to fuel the global bone glue market.

Globally, the demand for bone glues is anticipated to rise significantly among orthopedic surgeons. Conventional treatment methods involving metal plates, rods, screws and even cementing materials are increasingly causing post-op complexities in patients. Researchers in the field of bone adhesive technology have been grappling to find a bone adhesive that is efficient in replacing the traditional metal plates etc. and is yet biocompatible. To this end, bone glue has emerged as an efficient, safe and biocompatible bone adhesive. Consequently, orthopedic surgeons are increasingly reluctant to utilize non organic materials for surgical purposes, thereby enhancing the sales of bone glues in the orthopedic market during the forecast period. However, the gradual R&D for the development of this product is anticipated to act as constrain for this market.

     

The bone glue market is segmented on the basis of product, therapeutic applications, end users and regions. Based on products, the market is segregated into synthetic bone glue and natural bone glue. On the basis of therapeutic applications, the market is classified into arthroplasty, sports injuries, spinal injuries and others. Hospitals, clinics, specialized orthopedics clinics and ambulatory surgical centers are a few end users of this market. Geographically, the market is divided into North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

The North American region dominates the global bone glue market owing to technological advancement in bone glue’s pharmaceutical production and robust healthcare infrastructure. However, the Asian Pacific market is expected to register high growth rate in the coming years owing to higher geriatric population and increased accident cases.

Some of the key companies in the global bone glues market are LaunchPad Medical, Tissuemed Ltd., Baxter International Inc., Cryolife, Johnson and Johnson, Cohera Medical Inc., Chemence Medical Inc., Integra Lifesciences Corporation, B.Braun Melsungen AG, Luna Innovations Incorporated, DENTSPLY SIRONA Inc., and C.R. Bard Inc.


Upcoming

Neuroendocrine tumors (NETs) emerge from hormone-producing cells of body’s neuroendocrine system and nervous system. NETs tend to release higher-than-normal amounts of hormones and impact negatively the important body organs such as the lungs, gastrointestinal tract, stomach and intestines and various body functions. These tumors may be benign or malignant in nature. Some examples of neuroendocrine tumors are carcinoid tumors, islet cell tumors, medullary thyroid cancer, pheochromocytomas, neuroendocrine carcinoma of the skin (Merkel cell cancer), small cell lung cancer, and large cell neuroendocrine carcinoma (a rare type of lung cancer). The tumors begins with infecting the intestine and form carcinoid tumors, followed by pancreas.

NETs can infect a range of glands such as thymus, thyroid, adrenal and pituitary gland. Efficient treatment for neuroendocrine tumor is extremely necessary because if the tumor is malignant in nature; it might spread to nearby tissues or lymph nodes, eventually spreading throughout the body. The treatment options for NETs are limited in number and include surgical removal of tumors, chemotherapy, targeted therapy and radiation therapy, etc. There is no standard treatment for treating neuroendocrine tumor but two novel targeted therapy drugs- Afinitor and Sutent have been approved by FDA for treatment of advanced pancreatic neuroendocrine tumors and is beneficial for some patients according to the type and severity of the indication.

Globally, increasing incidences of NET among patients mainly due to disorders such as Multiple endocrine neoplasia type 1 (MEN1), Multiple endocrine neoplasia type 2 (MEN2), Neurofibromatosis type 1 (NF1), Von Hippel-Lindau syndrome (VHL) and Tuberous sclerosis complex (TSC) disease. However, in October, 2017, JAMA Oncology Journal published an article stating that the survival rate for all Neuroendocrine Tumor Treatment Market has improved, especially for distant-stage gastrointestinal Neuroendocrine Tumor Treatment Market and pancreatic Neuroendocrine Tumor Treatment Market. This is attributed to availability of better therapies and early detection and diagnosis techniques. Thus, introduction of new therapies and extended indications for approved drugs is expected to augment NET treatment industry. Targeted therapy is one of the most preferred methods to treat neuroendocrine tumor. Such innovative and highly effective approach for treating cancers is also responsible for gaining traction during the forecast period.

Increasing adoption of advanced diagnostic imaging techniques such as endoscopic ultrasonography etc. would result in discovery of NETs which are small in size and are relatively clinically insignificant. These kind of tumors are not related to the symptoms and may not require surgical excision and hence, requiring other techniques for treating the tumor, resulting in fueling the market.

The neuroendocrine treatment market is segmented on the basis of drug, indication, end user and geography. Based on drug, the NET market is categorized into Everolimus, Sunitinib Malate, Lu-Dotate, Lanreotide, and Octreotide. On the basis of indication, the segment is bifurcated into gastrointestinal neuroendocrine tumor, lung neuroendocrine tumor, pancreatic neuroendocrine tumor and others neuroendocrine Tumor. Whereas, hospitals, oncology centers, and others including GI centers, cardio-thoracic centers, NET centers are few end users in this industry. Geographically, the NET treatment market is bifurcated into North America, Europe, Asia Pacific, Middle East &Africa and Latin America.

The North America region is expected to dominate the neuroendocrine tumor treatment market during the forecast period owing to the establishment of various national universities and small scale pharmaceutical companies researching and developing effective drug for NET, capable of modifying clinical approach to treat neuroendocrine tumors. Thus, pharmaceutical and biotechnology companies have a major opportunity to progress in the U.S. NET treatment industry.

Some of the key players of NET treatment market are Advanced Accelerator Applications, Novartis AG, Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc., Ispen, Tarveda Therapeutics, Exelixis, Inc., Pfizer Inc, and Progenics Pharmaceuticals, Inc


Upcoming
Medicinal cannabis, or medicinal marijuana, is a therapy that has garnered global attention owing to its application in treatment of chronic ailments and the controversies surrounding legal, ethical, and societal implications associated with application. Cannabis has more than hundred active compounds, two of which are -- Cannabidiol (CBD) which does not alters the consciousness and is used for medicinal properties and another component include delta-9-tetrahydrocannabinol (THC) which causes intoxication.

Medicinal usage of cannabis is performed to curb disease or health conditions such as blood pressure, memory, concentration, appetite, sensory stimulus, glaucoma, seizures, weight loss, schizophrenia, multiple sclerosis (MS), Huntington’s disease, anorexia, chronic motion sickness, failure to thrive in infants and post traumatic stress disorders (PTSD) in veterans. Cannabis is also alluring for consumers since it is relatively safer to use as compared to opiates. Moreover, marijuana is known to be a fantastic muscle relaxant and appears to ease the pain of multiple sclerosis, lessen the tremors in Parkinson’s and nerve pain. Additionally, medicinal cannabis’s application in treatment of fibromyalgia, endometriosis, interstitial cystitis, irritable bowel syndrome, Crohn’s disease has been successful. Furthermore, pain and wasting syndrome associated with HIV and other conditions of chronic pain have also found cannabis as significant medicine in their treatment methods is projected to accelerate the market growth over forecast period.

Growing R&D activities in the medical cannabis market and gradual approval of medicinal cannabis products globally are also expected to enhance the market growth. For instance, in March, 2017, the German parliament signed a law allowing the use of cannabis for medicinal purposes if it is prescribed by a medical practitioner to a patient suffering from severe health issues such as chronic pain, vomiting, and nausea. Moreover, purchase of cannabis products is allowed from pharmacies on the basis of a valid prescription. However, cultivation of marijuana is still a criminal offence in many countries. Thus, suppliers depend on other economies to import medicinal cannabis implying a huge potential for growth of the medicinal cannabis industry in pharmaceutical and biotechnology companies. However, consumption of cannabis excessively may induce tachycardia or increase the risk of heart attack, particularly for users with existing heart disease or arrhythmias and is therefore a constraint for the growth of the industry.

The medicinal cannabis market is segmented on the basis of point of sale, active ingredient, therapeutic application and geography. The point of sale segment is further bifurcated into dispensaries, online pharmacy and hospital pharmacy. On the basis of active ingredient, the market is classified into Tetrahydrocannabinol (THC) and Cannabidiol (CBD) whereas based on therapeutic application, the market is bifurcated into pain, arthritis, neurological disease neurological applications and other applications. Furthermore, neurological applications is segmented into epilepsy, multiple sclerosis and other neurological applications. Geographically, the market is divided into North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

The North America region is expected to dominate the market over the forecast year owing to legalization of Marijuana in U.S. In the U.S., manufacturers of Medicinal cannabis are focusing on expansion of their product business. For instance, in July 2016, Insys Therapeutics, Inc. received the U.S. Food and Drug Administration (FDA) approval for dronabinol oral solution- Syndros, an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol is indicated to be used in the treatment of anorexia pertaining to AIDS and cancer chemotherapy-induced nausea and vomiting. Furthermore, in 2016, Medical Marijuana, Inc. launched the HempMeds Mexico which is a CBD hemp oil product and the company intends to expand its cannabis business in the Latin America. 

The market in Middle Easter and Africa region is estimated to grow during the forecast period. Among the GCC countries, Israel has approved the medical cannabis product. In Africa region, the governments in Lesotho and Malawi in South Africa have granted the license for medicinal marijuana in 2017 and Verve Dynamics, a Cape Town-based alternative medicines company has received a license from the government of Lesotho to cultivate the cannabidiol (CBD) medicinal cannabis.

Some of the key players operating in the global medical cannabis market include Medical Marijuana Inc. ,Aphria, Inc., Aurora Cannabis, Inc., MGC Pharmaceuticals Limited, Tilray, Medreleaf Corporation, BOL Pharma, Canopy Growth Corporation, Insys Therapeutics Inc. and GW Pharmaceuticals, plc.


Upcoming

Nanomedicine is an application of nanotechnology in the field of diagnosing, treating and preventing disease and traumatic injury, of relieving pain, and improving human health with the application of molecular knowledge and tools. It is a combination of five sub-disciplines Nanomaterials, Novel Therapeutics and Drug Delivery Systems, Nanodevices, Analytical Tools Nanoimaging and Clinical, Regulatory and Toxicological Issues.

Nanomedicine aims at comprehensive monitoring, repair, control, defense, construction and improvement of all human biological systems, working from the molecular level using engineered devices and nanostructures, eventually aiding human health. All the active components ranging from the size of one nanometre to hundreds of nanometers are included as nano-components. The focus of nanomedicine is the nanointeractions within a framework of a larger device or biologically, within a cellular/sub-cellular system.

A range of effective healthcare products based on nanomolecule are in pipleline and withhold the potential avenues for growth of nanomedicine market. The products that are recorded to be in phase II of clinical development are anticipated to be commercialized over the coming decade thereby influencing revenue generation over the forecast period. Personalized medicines and effective treatment for eradication of genetic abnormalities are also expected to fuel market growth.

In Europe, application of nanosized drug delivery system in routine clinical use has showcased promising results.. Application of nanomedicine in drug delivery systems can be attributed to the physicochemical properties exhibited by nanoparticles which allows delivery of drug by enhancing cellular penetration and lowering drug toxicity is revolutionary and presents drug delivery as an emerging product line thereby fueling market growth.

Oncology and cancer treatment utilizes this technique for creating products for diagnosing and treating cancer. Application of nanomedicine in cancer treatment is anticipated to serve as a tool for active and passive targeting of cancer thereby impacting the nanomedicine market in oncology positively.

                  

Nanomedicine market is segmented on the basis of product, technology, application and region. Based on product, the market is segmented into therapeutics, regenerative medicine, in-vitro diagnostics and in-vivo diagnostics vaccines. The market is bifurcated in Clinical Oncology, Infectious diseases, Clinical Cardiology, Orthopedics and Others on the basis of application. The type segment is further bifurcated into Nanoparticles, Nanoshells, Nanotubes and Nanodevices. The nanoparticle segment is further divided into metal and metal oxide nano particles, Liposomes, Polymers & polymer drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles.  The nanoparticles segment under type segment, is further bifurcated into metal and metal oxide which is further segregated based on type and application. The type segment comprises sub segments including Gold Nanoparticles, Silver Nanoparticles, Iron Oxide Nanoparticles, Alumina Nanoparticles, Gadolinium Oxide Nanoparticles and Others. The application segment comprises In-vivo Imaging, Targeted Drug Delivery, Proton Therapy, In-vitro assays, Cell & Phantom Imaging. The market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East and Africa on the basis of region.

The North America region is expected to dominate the nanomedicine market owing to advancement in healthcare and sophisticated healthcare infrastructure. Additionally, favorable government policies supporting the R&D funding to obtain promising results also contributes to the North America’s strong hold in the regional market. Furthermore, growing partnerships between private enterprises and nanomedicine startup organizations also contribute to North America’s leading position in the market. However, the Asia Pacific region is also anticipated to witness lucrative growth over the forecast period owing to rise in number geriatric population, increased research grants and growing demand for prophylaxis of life-threatening diseases. Furthermore, increasing international research collaborations and venture capital investors from developing economies are also expected to propel growth in nanomedicine market over the forecast period.

Major players operating in the market are Arrowhead Research, Teva Pharmaceutical Industries Ltd, Merck & Co. Inc., Ablynx NV, Celgene Corporation, Abraxis Bioscience Inc., Nanosphere, Inc., Combimatrix Corp, GE Healthcare, Combimatrix Corp, Pfizer Inc.


Upcoming

Nootropics, also referred as cognitive enhancers and smart drugs are supplements, drugs and other substances utilized to improve cognition, concentration and basic functioning of human brain. These enhancers are made up of natural extracts which are beneficial for executive functions, particularly creativity, memory and motivation, in healthy individuals.  The enhancers also include multivitamins, caffeine and other substances under Generally Regarded as Safe (GRAS) category prescribed by Food and Drug Administration (FDA) and therefore, nootropics are considered as essentially dietary supplements. Although, nootropics have been around since 1970s, and started gaining traction when popularized by biohackers as a brain-fog and stress level reducing marvel.

Nootropics are specifically engineered to help consumer’s mind and body to perform optimally. Nootropics help in improving the mood and boosting an individual’s energy levels, increases focus and feelings of mental clarity. Furthermore, nootropics also promotes restful and deep sleep, improved cellular health, anti-aging benefits and also helps in feeling better for the entire day. The benefits offered by smart drugs for enhancing brain function is further projected to witness growth over the forecast period.

Nootropics also claim promising benefits which include motivation, focus and memory boosting and has been supported by research. Nootropic is repackaged and sold to overachievers at the academic and professional level aiming to enhance their brain function. Increasing population of depression and emotional and mood disorder globally is expected to positively lead to the acceptance and developments of the smart drug in the industry. Furthermore, increasing number of self-directed consumers, strong desire to enhance the brain function among the adult population, and the high penetration of promotional activities carried by the industry players are also influencing the market demand positively.

The company’s manufacturing nootropics are promoting the smart drug as a lifestyle brand via smart marketing and are also aiming to promote it as a healthcare brand after getting FDA approval. Various research and development labs and study groups are working towards this end. Few of the nootropic products widely used in the market includes

Nootropic market is segregated based on the applications which include memory enhancement, mood and depression, attention and focus, anti-aging and longevity, recovery, sleep and dream enhancement and anxiety. The memory enhancement product is expected to hold the largest revenue share over the forecast period owing to the benefits associated such as enhanced learning, memory effect and protection of the brain from chemical injuries. The marketing strategies for nootropic have developed a customer base in students, executives as well as in the older generation, owing to their promised benefits. Easy accessibility and the booming market for supplements has also increased the market demand.

Increase in awareness of consumers for a better cognitive and preventive health, enhanced number of self-directed consumers and channel proliferation is also anticipated to spur the growth over the forecast period. Although, lack of product knowledge and awareness as supplements may hinder the market growth over the forecast period.

Geographically, North America regional market is considered to be the major consumer of the smart drug and is also characterized by domicile of topmost industry players. High awareness in consumer population for cognitive and preventive health is expected to drive the regional market. Asia Pacific region is projected to be the fastest progressing regional market for nootropics. Countries such as India and China, with a history of natural and herbal based cognitive drugs, the foreign investment in collaboration with local players have substantially determined market growth and opportunities.

The collaboration has allowed the local players to utilize the knowledge of a local drug and manufacture a nootropic product benefitting the companies in establishing a customer base in dietary supplement market in countries where natural/herbal drugs are considered effective. For instance, India and China, Ayurveda and Traditional Chinese Medication respectively offers various effective drugs for cognitive betterment.

Major key player in the nootropics market include Nootrobox Inc., Cephalon Inc., PureLife Bioscience Co. Ltd., Peak Nootropics, Nootrico, SupNootropic Biological Technology Co. Ltd., AlternaScript LLC, Accelerated Intelligence Inc., Onnit Labs LLC, Powder City LLC, Ceretropics, Nootropic Source, and Clarity Nootropics.


Upcoming

“Targeted” diagnostics and therapeutics are one of the latest and anticipated healthcare technologies on the block. Genomic and proteomic sciences have brought the concept of personalized medicine that leverages knowledge of genetic makeup to build a more personalized approach to healthcare. Personalized Medicine is essentially a treatment process that is tailor made for the individual characteristic of a patient. Individual characteristic involves a patient’s unique molecular and genetic profile which is either responsible for or is susceptible to diseases like cancer, cardiovascular diseases, neurodegenerative disorders or other diseases. Personalized Medicine involves scientific breakthroughs that allows to predict the kind of medication and treatment method suits a particular patient, instead of following a generalized method of treatment. One of the advantages of personalized medicine over traditional healthcare is its precise approach cuts down costs of treatment considerably as compared to the “trial and error” method of treatment.

Pharmaceutical companies’ revenue was so far majorly based on “one-size-fits-all” medicines manufactured by them. However, the advancements in genetics and advent of Next Generation Sequencing (NGS), knowledge of a patient’s exact genetic makeup has become possible and it was evident that an individual’s disease is as unique as their genetic structure. Therefore, drug makers are developing tools which can decipher minute inborn differences for making certain individuals particularly susceptible to certain diseases. The drug makers are developing a safer, more potent drug which can target the biological differences forming the basis of diseases more precisely. Their target is to produce a myriad of personalized medicines that can yield huge profits over the forecast period.

Personalized medicines are related to the field of pharmacogenomics, pharmacogenetics, pharmacoproteomics and metabolomics. Basic technologies of molecular diagnostics like single nucleotide polymorphism (SNP) genotyping and biomarkers play an essential role in personalized medicine. It also involves biological therapies which may use patient's own cells that may or may not be tumorous. Vaccines, Monoclonal antibodies are therefore directed to specific genetic and immunologic targets. There is an increased focus on early detection and prevention of disease by using Biochip/microarray technologies and next generation sequencing in modern medicine. Thus, personalized medicine will involve a great deal of knowledge in nanobiotechnology, bioinformatics, genetics and pharmacology.

Lower probability of medication flaws, rapid results and customized effects and adverse drug reactions are few major factor behind the increased traction for R&D and revenue potential of the medicines. Furthermore, increasing favorable government policies for personalized medicine and development of genetic databases is also expected to add potential opportunities to boost the market growth.

Although, the advent of personalized medicines can bring an increase in quality of clinical care, thus, decreasing the cost of healthcare, with a handful of diagnostic tests and medicines and are expected to adapt by the market over the forecast period. Thus, the market is still projected to overcome challenges like ethical issues regarding tissue engineering and some major barriers related to economics.

The global personalized medicine is segmented based on the therapeutic area, and end-user. The therapeutic area segment is further bifurcated into oncology, neurology, antiviral, cardiology, psychiatry and others whereas the end-users segment is segmented into hospitals, molecular diagnostics laboratories and testing facilities, contract research organizations, academic institutes and research laboratories, bio and health informatics companies and others (venture capitals, service providers).

The demand of personalized medicine is projected to increase over the forecast period and has resulted in Pharma companies to accelerate the research entailing drugs that come under personalized medicine. Pfizer’s drug Xalkori and Roche's drug Zelboraf, both of which are personalized medicine and are prescribed for certain types of cancer were one of the fastest through the pipeline in recent years. Some of the leading companies in this field are Roche, Johnson & Johnson's, Novartis, AstraZeneca, Bristol-Myers Squibb, Pfizer, Eli Lilly, Sanofi, Amgen, Merck and GlaxoSmithKline.


Upcoming

Tuberculosis (TB) is classified as an infectious disease that is caused by Mycobacterium tuberculosis that generally infects human lungs. However, it can also affect other body parts or organs. The other three major types of tuberculosis that are found include latent, active, as well as drug-resistant tuberculosis. The symptoms of tuberculosis cannot be identified in case of latent tuberculosis, owing to the presence of an inactive form of bacteria. However, in active tuberculosis, the symptoms are clearly visible and these symptoms can spread from one person to another. Some of the common symptoms of active tuberculosis include unintentional weight loss, coughing for more than two weeks, chills, coughing up blood, chest pain, fever, loss of appetite and fatigue. The major risk factors generally linked with tuberculosis include diabetes, HIV/AIDS, malnutrition, cancer, and severe kidney disease.

Large number of tests such as blood tests, imaging tests (such as chest X-ray or CT scan), and sputum tests can be used to diagnose. Tuberculosis can be treated with either the first-line or second-line therapy. According to the report by World Health Organization (WHO), tuberculosis is one of the major causes of deaths that occurs across the globe. Currently, over 9 million new cases of TB and 1.5 million deaths is caused by tuberculosis that occurs across the globe. At present, WHO and some government agencies are working toward diminishing the burden of tuberculosis across the globe, with the support of programs such as Stop TB. For instance, in the year 2015, Multi-Drug Resistant Tuberculosis Program was initiated in order to check the prevalence of tuberculosis across the world.

Factor such as rising prevalence of multi-drug resistant tuberculosis is fuelling the tuberculosis drugs market growth. The major constraint for tuberculosis market includes drug shortage, especially in low- to medium-income countries of the globe. Tuberculosis linked with diseases such as HIV/AIDS and other conditions such as obesity is highly difficult to manage.

The global tuberculosis drugs market can be classified based on drug class, disease type, end-user, and region. Based on drug class, the global tuberculosis market can be segmented into first-line therapy, second-line therapy, and combination therapy. The first-line therapy of tuberculosis includes Isoniazid, Pyrazinamide, Rifampin, and Ethambutol; while Ethionamide, Streptomycin, Levofloxacin, Capreomycin, and Gatifloxacin are mostly considered as a part of the second-line therapy. The second-line therapy is projected to be the swiftly growing segment of the global tuberculosis drugs market.

Depending upon disease type, the tuberculosis drugs market can be divided into latent tuberculosis, active tuberculosis, and drug-resistant tuberculosis. The drug-resistant tuberculosis market segment is anticipated to grow rapidly during the future years.

On the basis of distribution channel, the global tuberculosis drugs market can be divided into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy market segment command the major share in the global tuberculosis drugs market. The segment is likely to expand at a high growth rate during the forecast years. The others segment is expected to gain majority of market share during the future years, owing to launch of national government programs.

Based on region, the global tuberculosis drugs market can be divioded into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia-Pacific regional market dominated the global tuberculosis drugs market. The major factors fuelling the growth of the market include presence of large pool of patient population and high prevalence of TB, especially in some of the developing countries of the region such as India and China. On the other hand, North America and Europe comprise of small-sized patient pool with low rate of incidence of the disease. However, high rate of adoption of advanced yet expensive TB tests high level of awareness, well-developed health care infrastructure, and high purchasing power are propelling the market growth in these regions.

The major players included in the global tuberculosis drugs market are Pfizer Inc., Sanofi, Novartis AG, Zydus Cadila, Lupin Limited, Merck & Co., Inc., Bayer AG,  and AstraZeneca. Inc.


Upcoming

One of the major cause of lung cancer is cigarette smoking and it also causes other respiratory and cardiac disorders. An increasing awareness pertaining to these health hazards has inclined individuals to adopt smoking cessation therapy. There has been a rise in awareness with the help of newspapers television advertisements, information brochures, as well as other media has proven to be highly effective in restricting the nicotine addiction crisis to some extent. All of these factors are propelling the nicotine based products segment market growth.

The introduction of novel products is another factor fuelling the growth of nicotine based products segment. Some of the other innovative players in the market are concentrating on the introduction of novel treatment substitutes such as selective partial agonists of nicotinic receptors (varenicline) and Tabex (Cytisine-plant-based alkyloid). Large number of clinical trials have been carried out in the specific population, such as adolescents and pregnant women in order to measure the safety as well as efficacy of these products.

The implementation of GCC Standardization Organization (GSO) in Middle East and African region has incorporated an anti-tobacco law that mandates the sticking of warning labels on tobacco products. It comprises of a picture-based health warning that encompasses half of a package front and back, with an Arabic warning encasted on the front and an English warning on the back.

The Tobacco Control Program at the Ministry of Health and Secretary of the Anti-Tobacco National Committee in tandem with the Ministry of Education and Municipality officials are resulting in the development of awareness campaigns in order to warn about the perils of smoking and banning all stores from marketing and selling tobacco products to people below 18 years. The overall market growth of the nicotine based products market segment will be driven by the presence of nicotine based products especially nicotine gums in the market during the forecast period.

China ranks among the top of the list of countries that essays out stringent laws and rules against smoking. As per the draft bill, smoking is forbidden in all indoor public places in China such as workplaces as well as public transport. The various outdoor restricted areas comprises of areas in direct contact with or in schools, historic sites, day care centers, children's hospitals and stadiums. Such rigid laws are forcing the people in China to drift towards nicotine based products and this is eventually casting a positive influence on the segment.

In the global Smoking Cessation and Nicotine De-Addiction products market, nicotine based products and e-cigarettes are expected to be the most attractive market segment among all product type segments. The non-nicotine based products segment is anticipated to be the least attractive product type market segment. The nicotine based products market segment is leading in the North America Smoking Cessation and Nicotine De-Addiction products market and is anticipated to be the most attractive market segment.

The Latin America nicotine based products market is conquered by the U.S. and Europe based manufacturers with the help of distributors. Majority of the European organizations such as Perrigo Company plc and Fertin Pharm are exporting their products to the Latin American region in order to enlarge their geographical reach and attain major market share.

Additionally, the market availability of OTC products through online channels is aiding the European and U.S. based manufacturers to distribute their products in an easy manner. The Asia Pacific Smoking Cessation and Nicotine De-Addiction products market is anticipating major growth owing to swelling business expansion of established companies in economies like India and Japan. Moreover, the Chinese economy is a major manufacturing hub of e-cigarettes and the region is dominated by various Chinese players and associated suppliers. The Indian nicotine gum market is highly commanded by organizations such as ITC, Cipla Ltd., GlaxoSmithKline plc and Dr. Reddy’s Laboratory (Novartis).


Upcoming

Biopharmaceuticals has come across as one of the major segments commanding huge growth potential within the healthcare field. The high demand for effective treatment and increase in per capita healthcare expenditure has resulted in double digit revenue growth for market players in recent years. The healthcare industry provides especially profitable growth opportunities, since majority of these products still have low market penetration rate among the population. The market is set to gain further market share, owing to budding treatment archetypes and rapid technical innovation such as cell therapy as well as regenerative medicines. 

The major biopharmaceutical companies are concentrating on increasing investments in the biopharmaceuticals and biomedicine sector, as the industry has led to higher return on investment as compared to generic drugs market. Thereby, the biopharmaceuticals and biomedicine market is characterized by rapid increase in consolidation.

The growth of biopharmaceutical and biomedicine market correlates with healthcare amenities, per capita healthcare expenditure, as well as research and development expense on the expansion of new products. In the year 2016, the global healthcare spending rose by 1.7% annually. Also, there has been an increase in prevalence rate of chronic diseases across the globe. The combination of these two aforementioned factors results in growth in demand for biopharmaceutical drugs. Though, the price of these drugs is moderately higher than generic drugs, there is a strong demand from end users that has resulted in rapid increase in sales of biopharmaceutical as well as biomedicine drugs. The development of novel concept of drugs coupled with anticipated commercialization of pipeline drugs is expected to further encourage the biopharmaceuticals and biomedicine market growth. Though this industry is gaining significant market share across the world, certain factors such as high operational costs, rigid regulatory compliances, and complexity of supply chain are major hindrances for stakeholders.

The global biopharmaceutical and biomedicine market is classified based on product type and branch of biomedicine. Depending on product type, the biopharmaceutical and biomedicine market has been classified into cytokines, recombinant therapeutic proteins, hormones, vaccines, allergenic, somatic cells, and monoclonal antibodies. Among these market segments, the vaccines segment commanded the major share of this global market.

Depending upon biomedicine branch, the biopharmaceutical and biomedicine market has been divided into nano medicines, gene therapy, biochips, cell technologies, system biology, and bioinformatics. Based on regions, the global biopharmaceutical and biomedicine market is divided into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

The transforming healthcare landscape and rate of adoption of substitute business operating model is set to fuel growth of North American region biopharmaceutical and biomedicine market. However, the Asia Pacific and Latin American region is expected to gain significant market share in the forecast period.

The major players included in the report are Apeiron Biologics AG, Quest Pharmatech, Inc., AMEGA Biotech, Teva Pharmaceutical Industries, OncoMed Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Eli Lilly and Company, Sanofi S.A., Sigma Aldrich Corporation, and Janssen Biotech, Inc.


Upcoming
Regenerative medicines possess the capability to repair, replace, as well as regenerate tissues and organs that are affected by either injury, disease, or ageing process. These medicines have the capability to restore the cells and tissues functionality and can be used in varied range of degenerative diseases such as cardiovascular, dermatology, neurodegenerative disorders, and orthopedic applications. The scientific researchers are focused on developing technologies dependent upon biologics, genes, somatic and stem cells. The stem cells possess the ability of proliferation and differentiation and thereby they are of vital importance in this sector. Presently, large number of treatments is available for degenerative as well as life-threatening disorders that do not offer cure. However, regenerative medicines possess the ability to either replace or regenerate the tissues as well as organs suffering from disease. Also, the utilization of nano-materials in wound care, drug delivery, as well as immunomodulation provides growth opportunities for the regenerative medicines market.

Factors promoting the growth of cell-based regenerative medicines market include technical advancements in tissue as well as organ regeneration, rising prevalence of chronic disorders and trauma emergencies, major potential of nanotechnology, and emergence of stem cell technology. Additionally, high incidence of degenerative disorders and organs shortage for transplantation are anticipated to fuel the market growth. The major potential of regenerative medicine to replace, repair, as well as regenerate damaged tissues as well as organs has propelled the market growth. However, rigid regulatory barriers and high treatment cost are likely to hamper the market growth.

The global cell-based regenerative medicines market can be classified based on therapy, applications and region. Further, on the basis of therapy, the cell-based regenerative medicines market is classified into immunotherapy, cell therapy, tissue engineering, and gene therapy. Based upon applications, it is segmented into oncology, orthopedic & musculoskeletal disorders, dermatology, and cardiology. 

Based on regions, the global cell-based regenerative medicines market is divided into North America, Europe, Asia-Pacific (APAC), Middle East & Africa (MEA), and Latin America. The North American region is highly attractive region in the global regenerative medicines market. This region is anticipated to be highly preferred for new entrants owing to the rising end-user applications. This region’s market is in its growing phase and is anticipated to demonstrate high potential in future, as majority of the therapies are in the final phase of clinical trials. This demonstrates the companies’ intervention for regenerative medicine products commercialization. The rising need of regenerative medicine products leads to favorable regulatory and reimbursement policies of government authorities. 

However, stringent regulatory policies related to stem cell technologies have lead to major challenges for the embryonic stem cells adoption due to ethical issues as well as controversies pertaining to its source; thereby, hindering the market growth. There has been an increase in consumer awareness related to the regenerative medicine benefits in the recent years that has led to high demand. The major companies that provide regenerative medicines include Acelity (KCI Concepts), Cook Biotech Inc. Organogenesis Inc., Vericel Corporation, Osiris Therapeutics, Inc., and NuVasive, Inc., Medtronic , Stryker Corporation, Integra LifeSciences, and C.R. Bard. 


 

Upcoming
Psoriasis is non-communicable autoimmune inflammatory, chronic, and painful skin disease characterized by abnormal skin patches. These skin patches are scaly, red, and itchy. These patches may be small and either localized or encompass the entire body. At present, there is no cure for this disease and the major  goal of treatment is to limit inflammation and formation of abnormal skin plaque. Factors such as rising disease prevalence, significant unmet needs, and large number of pipeline molecules would drive the psoriasis treatment market growth across the globe.

There are five different psoriasis types namely Inverse, Plaque, Pustular, and Erythrodermic. The most common type of psoriasis is called Plaque psoriasis or psoriasis vulgaris, and accounts for over 90% of reported cases. The majorly affected body areas include around the navel, back of the forearms, shins, and the scalp. The guttate psoriasis is characterized by drop-shaped lesions while in pustular psoriasis small non-infectious pus-filled blisters are seen. Inverse psoriasis leads to the formation of red patches in skin folds. Erythrodermic psoriasis occurs on widespreading of the rash and develops into other types. At some point of disease, the fingernails and toenails are affected in most people. This may include nails pits or lead to transformation in nail color.

Factors promoting the growth of psoriasis market include availability of varied treatment options for psoriasis, use of light therapy for psoriasis and rising prevalence of psoriasis coupled with early diagnosis.

 Different treatment methods can aid to control the psoriasis symptoms that is fuelling its treatment market growth. The different treatment methods include administration of steroid, vitamin D3, exposure to ultraviolet B (UVB) light, and immunosuppressive like methotrexate. Over 75% of the cases can be treated with creams alone. Cream and ointments of corticosteroid, and calcipotriol can help to treat mild-to-moderate psoriasis. However, in cases of severe psoriasis, creams are coupled along with oral medications such as methotrexate, acitretin, and cyclosporin.

Various topical drugs that are used in psoriasis treatment include hydroxyanthrone, corticosteroids, vitamin D, and retinoid. For the treatment of mild-to-moderate psoriasis, topical corticosteroids are often prescribed. However, low-potency corticosteroid ointments can be used for sensitive areas such as face or skin folds and for the treatment of widespread damaged skin patches. Medicated foams as well as scalp solutions are available in market for the treatment of psoriasis scalp patches.

The global psoriasis treatment market can be classified based on drug class, route of administration and region. On the basis of drug class, the global market is classified into TNF inhibitors, vitamin D analogues, interleukin blockers, topical corticosteroids and others. Further based upon route of administration, it is segmented into topical therapeutic, oral therapeutic,and parenteral therapeutic drugs. 

Based on regions, the global psoriasis treatment market is divided into North America, Europe, Asia-Pacific (APAC), Middle East & Africa (MEA), and Latin America. The North American region is anticipated to command the maximum market share and would lead the psoriasis treatment market during the forecast period. Factors such as large patient pool, better medical facilities, commercialization of new diagnostic technology, medical policies, and favorable reimbursement policies are fuelling the growth of this market. 

The major companies that provide psoriasis treatment include Johnson & Johnson, Glenmark Pharmaceuticals Limited, Cipla Ltd., Sun Pharmaceuticals Industries Ltd., Stiefel Laboratories Inc. (GlaxoSmithKline plc), Win Medicare Pvt. Ltd., Rowan Bioceuticals Private Limited, and Novartis AG. 


 

Upcoming
An emerging disease treatment approach which is built based upon individual variability in genes, environment, and personal lifestyle is referred to as precision medicine. The precision medicine can also be termed as personalized medicine. Precision medicine is a mode of medicine that joins standardization with individualization. The benefit offered by this approach of treatment include accurate treatment prediction and strategies for prevention of a particular disease that works for a particular group of people. The standardized medicines marketed have the limitation of a ‘one-size fits-all’ approach, which may or may not be suitable for every patient owing to genetic differences. 

Precision medicine is a relatively novel concept and technology that has now become a major business investment domain for major pharma companies. With the help of precision medicine,  the diagnosis as well as diseases treatment is easier by depending on genomics as well as specific biomarker techniques. A precision based approach helps to to formulate medicines that result in new insights into disease biology. Thus, it becomes easier for physicians to make selection of  the right drugs, optimal dosage and time for medicine usage coupled with least side effect. 

Moreover, high awareness pertaining to the benefits of adaptation of precision medicine is promoting this market growth. Other factors such as intense research, along with severe unmet needs in various diseases, especially oncology is further bolstering the market growth. Moreover, favorable government regulations and support in developed economies is driving the market growth. However, the high price of these therapies is expected to hamper the market growth.

The global precision medicine market has been segmented based on the type of technology, application and geography. On the basis of type of technology, the precision medicine market has been classified into big data analytics, sequencing, companion diagnostics, drug discovery, and bio-informatics. Depending upon application, Based on application, the global market is divided into neurology,   cardiology, oncology, Infectious disease, hematology, endocrinology and others. Based on regions, the global precision medicine market is divided North America, Europe, Latin America, Asia Pacific, Latin America and Middle East and Africa.

The North American market is anticipated to be the major markets in the precision medicine market. Factors such as high rate of adoption of leading edge technologies, favorable legal environment owing to certain grants and initiatives granted by the government are leading to high regional market growth. For instance, in January 2015, the U.S. President launched the Precision medicine initiative that included high funding request of US$ 215 million in the 2016 federal budget. The G erman precision medicine market is anticipated to register considerable growth over the future years. Supportive government initiatives such as launch of Individualized Medicine action plan coupled with increasing use of electronic health records for optimum healthcare outcomes is set to drive regional market growth.

Some of the industry players in precision medicine market include Quest Diagnostics. F-Hoffmann La Roche, Novartis AG, Teva Pharmaceuticals, Qiagen, Inc., Medtronic, Illumina, Inc. and  Pfizer, Inc. 


 

Upcoming
An opioid is a form of narcotic pain medication that is utilized to treat moderate to severe pain. The opioids are used as diarrhea suppressant, anesthetic, cough suppressant, and to decrease surgical pain, pain arising from disease, cancer pain and injury or trauma.  These substances are majorly utilized in cancer pain management as well as end-stage diseases in which palliative care is needed. However, these opioids can be addictive owing to their analgesic nature.

Factors such as intense focus of generic manufacturers towards Abuse-Deterrent Formulation (ADF), rising palliative care facilities, and reformed regulations for opioids prescription are anticipated to fuel the opioids market growth in North America and Europe. Intense focus on palliative care and increasing healthcare expenditure are major factors that propel the opioids market growth. Also, rise in the incidence of orthopedic disorders & chronic pain are expected to fuel the market growth. Also, increase in disposable income and upsurge in the global aged population are expected to drive the global opioids market growth. However, the emergence and cannabis legalization as an opioids alternative are expected to hamper the market growth.

The global opioids market is segmented on the basis of product type, application, and geography. Depending on product type, it is segmented into morphine, codeine, meperidine, methadone, fentanyl, and hydrocodone. Based on application, the opioid market is classified into diarrhea treatment, pain management, and cough treatment. The pain management market segment is further sub divided into back pain, osteoarthritis pain, neuropathic pain, cancer pain, migraine and others. 

Based on regions, the global opioids market is divided into North America, Europe, Asia-Pacific (APAC), Middle East & Africa (MEA), and Latin America. North America commands the majority of the market share, followed by Europe in the global market. It is anticipated that the rate of growth of opioids market will rise in Asia-Pacific region during future period. Also, the major companies are focusing on emerging countries to tap the market share and expand customer base as well as to meet the rising demand form this region. 

The major companies that provide opoids include Sun Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., Pfizer Inc., Actavis Plc., Janssen Pharmaceuticals, Inc., Boehringer Ingelheim, Sanofi, Mallinckrodt Pharmaceuticals, Purdue Pharma, and Egalet. 


 

Upcoming
As per statistics provided by the World Health Organization (WHO), about half of the world population is at risk of malaria. This has resulted in an increased preference of various healthcare agencies towards addressing this major problem. The other non-profit organizations such as the Melinda Gates Foundation and PATH are working towards the development of preventive measures as well as saving various lives in the malaria hit regions. The largest number of malaria cases are registered in Africa and therefore, this region is the major target of launching the novel malaria vaccine developed by GlaxoSmithKline plc. The European approval was granted to Mosquirix in 2015 and is currently being examined in Africa as a pilot study.

The African people utilize insecticide-treated mosquito nets as well as indoor-insecticide spraying for protection against malarial vectors. In Africa, the usage of insecticide-treated mosquito nets increased by 80% during the period of 2010-2015. Also, large number of mosquito repellent products such as coils, patches, mats, creams, liquids and others are marketed across the globe. The non-profit organizations are  also engaged in providing cheap and free treatment facilities to the people suffering from malaria in Africa. Also, GSK has thought of selling the vaccines at lower cost forgoing its huge profit margins in order to support the worldwide malaria eradication programs. Further, owing to the presence of more malarial vaccines under research pipeline, the malaria vaccines market is expected to  grow in future.

Factors promoting the growth of malaria vaccines market include high demand for vaccines for important diseases owing to rising focus on biological preparations. Also, various governments across several countries as well as companies, and non-profit organizations are contributing towards preventing the spread of this disease. The governments across various regions are majorly involved in programs targeted at curbing malaria. For instance, WHO had  withdrawn funding for pilot program in first phase during 2017 and 2020 by the global fund to combat against malaria and other disease such as AIDS and tuberculosis that are prevalent across the globe.

In 2015, WHO established a global technical strategy for malaria 2016-2030 with some defined goals. One of the major goals aimed at curbing malaria in at least 10 countries. The Indian government has recognized certain Drug Distribution Centers (DDCs) and Fever Treatment Depots (FTDs) in the rural areas for offering ease of access to anti-malarial drugs. Various government programs are being regularly monitored and are under surveillance to reduce malarial cases. This kind of support from these national as well as global initiatives will fuel the malaria vaccines market growth during the future period.

Based on regions, the global malaria vaccines market is divided into North America, Europe, Asia-Pacific (APAC), Middle East & Africa (MEA), and Latin America. The North American region is anticipated to command the maximum market share and would lead the malaria vaccines market during the forecast period. However, the Asia-Pacific and Middle-Eastern regions is anticipated to register swift growth during the forecast period owing to the large patient population. 

The major companies that provide malaria vaccines include GlaxoSmithKline Plc, Sanaria Inc, Sumaya Biotech, GenVec Inc, and Nobelpharma Co., Ltd. 


 

Upcoming
Phototherapy is as of now seemingly the most far reaching treatment in babies aside from couple of prophylactic medicines. Phototherapy or light treatment is a strategy which includes presenting the skin to light sources all the time. Be that as it may, now a days home phototherapy gadgets are additionally very prevalent. This remedial component was found in England in the 1950s and is widely utilized as a part of stylish pharmaceuticals for instance hyperbilirubinemia, neonatal jaundice and different other skin issue like psoriasis, skin break out vulgaris, skin tumors and dermatitis. National Health Survey (NHS) report recommend that since 2000 there has been an expansion in nonsurgical restorative techniques and light treatment gear by 147%. 

The light or radiation created by a restorative gadget is normally called as a phototherapy units/lamp.[AD1] These medicines can be conveyed to the skin of the entire body or it can be specifically focused to influenced ranges to decrease introduction of uninvolved skin. Not just in newborn children the phototherapy units are additionally utilized as a part of the treatment of pregnant and nursing ladies, and even immuno-stifled people as a large portion of the phototherapy units has none or not very many of reactions.

A large number of individuals over the world are experiencing skin[AD2] . These disarranges hugy affect the patients' day by day lives. However today, these skin illnesses can be dealt with. Phototherapy is a compelling and demonstrated technique for treatment. For instance, in 2014-2015, there were 20 million tasteful medicines performed crosswise over North America. So also, expanding interest for stylish medications in other created nations pushes the market development. 

Phototherapy lights and units for aesthetic pharmaceutical are prominently utilized as a part of enhancing corrective appearance. It has assorted applications which incorporates limiting indications of maturing like skin laxity, liver spots and wrinkles. Photograph treatment units likewise assume a noteworthy part in the treatment of inordinate fat, stoutness and cellulite. For instance in 2013 - 14 there were 55,000 corrective surgery systems performed in UK only.[AD3] In those restorative surgeries, surgical stylish methods shared 10% of the corrective methodology and non-surgical strategies represented the staying 90%. Mechanical developments in the field of makeup; expanding interest for phototherapy treatment for stylish solution among youth and elderly populace are fortifying the development of worldwide phototherapy lights and units for tasteful prescription market. Different components are expanding dispensable wages in creating nations, for example, India, China, and Brazil having generally high volume of skin sicknesses and disease patients are empowering the development of the worldwide phototherapy lights and units for tasteful medication. Notwithstanding, a few dangers, symptoms prior and then afterward treatment, intricacies after or amid stylish solution treatment, constrained repayment scope by protections and organizations for restorative and also tasteful prescription treatment are a portion of the key components limiting the market development. 

The global phototherapy lamps and units for aesthetic medicine market is segmented on the basis of treatments, configuration, source of light, end-users and geography. The global market is segmented on the basis of treatments as vitiligo, psoriasis, acne vulgaris, wound healing, cancer, and others. Based on configuration, the global market is classified as fixed units and mobile units. The global market is segmented on the basis of source of light as UV light, infrared light, LED light, halogen light, fluorescent light and others. The market is also classified into skin care, & cosmetic clinics, hospitals, ambulatory centers, research institutes, home care, fitness & wellness centers on the basis of end-users. The global phototherapy lamps and units for aesthetic medicine market is segmented based on regions as North America, Europe, Asia-Pacific, Latin America and Middle East and Africa.  

Some of the major companies in the global phototherapy lamps and units for aesthetic medicine market are GE Healthcare, Philips Healthcare, Drägerwerk AG & Co. KGaA, Medtronic plc, Masimo Corporation, HBW Technology, Gamma Star, Hill Laboratories, and Koninklijke Philips N.V. 


Upcoming
The term sterile injectables are used to refer biologics that are utilized for the treatment of different drugs and possess similar active ingredients as that of the branded drugs. However, there can be various types of inactive contents of the drugs. The manufacturing process of generic sterile injectable is same as that of FDA regulatory terms for the branded counterparts.

As per the latest studies, there are over 2,400 sterile injectable products under development phase that will result in the advent of advanced products in the global sterile injectables market. However, the major driving factor of this market includes generic injectables products market. Large number of pharmaceutical firms is concentrated on development of generic injectables. Owing to the increased focus of firms on therapeutic segments such as oncology, biologics have become an integral component of the pharmaceutical industry’s development pipeline. Also, novel drug delivery systems that offer targeted therapies are gaining importance. Also, the regulatory body has reduced the approval timeline for biologics. These factors are leading to the expansion of sterile injectables market. 

However, the expansion as well as manufacturing process of sterile injectable products is very complex and needs large investment. Also, the manufacturing costs of injectable products are high as compared to conventional drugs. Further, the U.S. FDA has imposed complex regulations on manufacturing facilities and equipment. Also, the operational costs of sterile injectables are high as majority of the injectables are toxic as well as infectious in their natural state and, therefore, require high quality and care in their storage, manufacturing, packaging, and distribution. These factors are challenging the growth of sterile injectables market.

The global sterile injectables market can be classified based on technology and region. On the basis of technology, the global market is classified into conventional dosages and novel formulations. Further based upon conventional dosages, it is segmented into solutions, and Lyophilized / Water for reconstitution. Based on novel formulations, the global market is further divided into depot injections, liposomes, nanoformulations, PEGylated formulations and implants. 

Based on regions, the global sterile injectables market is divided into North America, Europe, Asia-Pacific (APAC), Middle East & Africa (MEA), and Latin America. The North American region is anticipated to command the maximum market share and would lead the sterile injectables market during the forecast period. The presence of numerous pharmaceutical organizations in the North American market and favorable regulatory environment as well as large population base have led to the high growth rate and high demand for sterile injectables. However, the Asia-Pacific region is anticipated to register swift growth during the forecast period owing to the presence of large number of companies engaged in the development of generic products. 

The major companies that provide sterile injectables include Amgen Corporation, Eli Lilly, Sanofi, Baxter International Inc., AstraZeneca plc, Merck & Co., Inc., Novartis AG, Abbvie, Novo Nordisk,Genentech,Johnson & Johnson.


Upcoming

Limb salvage is otherwise called appendage saving surgery. It is a surgical system by and large performed to evade removals because of bone tumors. Limb salvage surgery replaces an ailing bone with a useful appendage embed. The danger of appendage misfortune is normally found in significant mishaps, growth tumors, diabetes, fringe vascular ailment and neuropathy. Limb rescue is more savvy and favored treatment design over removal in a long run. There are numerous Limb salvage methodology which incorporates compound folds with various tissue segments, skeletal recreation; ligament exchange or reproduction to reestablish the typical capacities and keep up security at the influenced joints. Limb salvage frameworks market involves metal prosthetic inserts, allograft i.e. a bone unite from someone else, or a mix bone join and metal embed i.e. allo-prosthetic composite. Likewise, the real players in the market additionally give metal prosthetics to any distal or proximal piece of the bone, for example, distal femur, tibial plate, proximal tibial bodies, proximal femoral segments and so on while prosthetic joints for add up to knee substitution and aggregate hip substitution frameworks are likewise incorporated into Limb salvage frameworks market. The strategy is by and large performed to treat bone tumors and delicate tissue sarcomas.

Appendage rescue frameworks market is developing, this is credited to expanding inclination of appendage rescue surgeries at the beginning time of danger to maintain a strategic distance from removal. Factors, for example, developing predominance of bone tumors, delicate tissue sarcomas and fringe vascular ailment and expanding frequencies of injury cases add to the income development of appendage rescue frameworks market. What's more, developing human services use, and rising protection scope additionally helps the development of appendage rescue frameworks market as expanding number of patients are selecting appendage saving systems. Additionally, accessibility of cutting edge appendage rescue frameworks drives the appendage rescue frameworks market, giving gigantic chances to the merchants inside this market. However post-agent complexities, for example, non-recuperating of the bones, appendage length error, contractures and prosthetic extricating hampers the development of appendage rescue frameworks market.

The global limb salvage systems market is segmented on the basis of type, end user, application and geography. On the basis of type, the global limb salvage systems market can be segmented into Allo-metal Prosthesis, Metal Prosthesis and Allograft. On the basis of application, the global limb salvage systems market can be segmented into Ligamentous Deficiencies, Significant Bone Loss, Multiple Arthroplasties, Bone Tumors and Others. On the basis of end user, the global limb salvage systems market can be segmented into Hospitals, Prosthetic and Orthopedic Clinics and Others. On the basis of geography, the global limb salvage systems market can be segmented into North America Latin America, Europe, Asia Pacific and Middle East & Africa.

Some of the key players operating in the global limb salvage systems market Biomet, Inc., Wright Medical Group N.V., Hanger Inc., Zimmer Inc., ONKOS SURGICAL among others.


Upcoming

Zoonotic diseases is the uncommon ailment that is generally spread from faunas to people and from people to faunas. There are different methods for diseases being exchanged, for example, air by coordinate contact, by contact with a latent question that harbors the illness, oral ingestion, and by creepy crawly. The infections from wiretaps and different faunas can make wiped out or demise in individuals. Numerous wellbeing offices all around have track on the illness and demise caused by zoonotic malady. The creatures dependably convey a few or the other infective pathogens that can be shared or transmitted with/to individuals. Zoonotic ailments might be caused by germs which including microscopic organisms, infections, parasites, and growths. Zoonoses when tainted can prompt a wide range of sorts of diseases in people and faunas which can be gentle to serious that human or creature may kick the bucket. It is constantly critical to see that the faunas don't generally seem sick or debilitated while conveying a zoonotic malady, numerous creatures do seem solid, however regardless they convey irresistible germs that can influence individuals to wiped out. Zoonotic diseases has turned out to be exceptionally normal now a days all through the globe. Yearly, evaluated, a huge number of Americans becomes ill from diseases spread amongst faunas and people.

Increment in the worldwide populace development, populace portability, and extreme urbanization, may make new zoonotic infections rise later on. Populaces in urban areas are unprotected to creature contact than rustic populaces, contingent upon the market structures and generation frameworks of live nourishment creatures, yet the urban populace may likewise live in all the more abounding situations helpful for diseases transmission. The developing interest for creature proteins prompting an expansion in the utilization of creature fats is probably going to add to the development of zoonotic ailment treatment market. For example, worldwide meat creation is expanded by almost 2% for each annum until 2015 and is probably going to develop later on. What's more, developing per-capita salary of the people may drive a wonder known as "nourishment progress" that is change from an eating regimen of rice, beans, and corn to one that joins more creature protein. This is probably going to build the ailments transmitted through zoonotic mode adding to the development of the zoonotic ailment treatment showcase. Nonetheless, absence of mindfulness about these maladies, the high ventures required on innovative work, and the high costs of the medications may hamper the development of zoonotic diseases treatment market.

The global zoonotic diseases treatment market is segmented on the basis of disease type, causative agents, drug type, end users and geography. By disease type, the global zoonotic diseases treatment market can be segmented into Rabies, Malaria, Viral Hepatitis, Tuberculosis, Relapsing Fever and Others. On the basis of causative agents, the global zoonotic diseases treatment market can be segmented into Nematode, Bacteria, Ticks, Rodents, Virus and Others. By drug type, the global zoonotic diseases treatment market can be segmented into Antibiotics, Antifungal Medications, Antibacterial Medications and Others. By, the global zoonotic diseases treatment market can be segmented into clinics and hospitals. On the basis of geography, the global zoonotic diseases treatment market can be segmented into North America

Some of the companies in the zoonotic diseases treatment market are Sanofi S.A., Novartis, Johnson & Johnson, GlaxoSmithKline, Pfizer, Inc., AstraZeneca, F Hoffmann-La Roche Inc. and BioCryst Pharmaceuticals, Inc., Ranbaxy and Cipla among others.


Upcoming

Regenerative medicines have the skill to replace, repair, and regenerate tissues and organs affected due to disease, injury, or natural aging process. These medicines are capable of returning the functionality of cells & tissues and are appropriate in a wide range of degenerative disorders such as cardiovascular, dermatology, neurodegenerative diseases, and orthopedic applications. Researchers focus on emerging technologies based on biologics, somatic, genes, as well as stem cells. Stem cells are capable of production and difference owing to which they are of importatnt in this field. Presently, many of the treatments are available for degenerative or life-threatening diseases do not deliver a cure and are palliative; however, regenerative medicines have the ability to replace or redevelop the tissues and organs suffering from disease or injury. Moreover, the utilization of nano-materials in wound care, drug delivery, and immunomodulation creates growth avenues for the regenerative medicines market.

The global regenerative medicines market has be categorized into product, therapy, application and regions. Based on the product the market has been segmented into acellular products, and cell-based products. On the basis of therapy the market has been divided into immunotherapy, cell therapy, tissue engineering, and gene therapy. Application segment has been bifurcated into diabetes, dermatology, cardiology, oncology, orthopedic & musculoskeletal disorders, central nervous system diseases among others.

The major factors driving the regenerative medicines market are the rise in the prevalence of genetic disorders and chronic diseases, private and government funding to support the research and development of regenerative medicine, rise in the growth of aging population, healthcare expenditure increased globally, and growing corporate partnerships to increase the development speed and commercialization of regenerative medicine. Lack of specified regulatory guidelines and ethical concerns with the help of embryonic stem cell for research and development are the major factors that may hinder the progress of the Regenerative Medicines market in the near future. Additionally the growing demand for the organ transplantation and strong product pipelines are some of the major growth opportunities for the Regenerative Medicines market players.

Geographically, the Regenerative Medicines market has been bifurcated into five regions North America, Europe, Asia Pacific, Middle East & Africa and Latin America. The Regenerative Medicines market size and forecast period for each region has been estimated from 2017 to 2023. Additionally the CAGR (%) for the forecasted period 2017 to 2023. The study also includes market estimates for major countries/regions such as the U.S, the U.K., Germany, France, Japan, China, India, GCC, North Africa, South Africa and Brazil. The detailed analysis by product, therapy, application and regions supports in evaluating the present scenario, growth prospects and the future scenario for the Regenerative Medicines market over the forecast period. Thus, the report delivers in-depth segment analysis of the market and classifies it into various industries, thereby providing valuable perceptions.

The growing expenditure in healthcare sector is anticipated to drive the APAC market for regenerative medicines in the future years. The major companies that are involved regenerative medicines Vericel Corporation, Osiris Therapeutics, Inc., Vericel Corporation, Integra Lifesciences Corporation, Medtronic PLC, Stryker Corporation, Cook Biotech Incorporated, Japan Tissue Engineering Co., Ltd., Organogenesis Inc., and Acelity L.P. Inc.


Upcoming

Cytotoxic, the name infers an operator or process that is lethal to cells. Cytotoxic Drugs are otherwise called hostile to tumor drugs. These medications work by interfering with cell development at specific stages in the development cycle. It works restraining the development of cells that are developing quickly, for instance tumor cells. Its system of activity includes debilitating of the cell film which prompts lysis of the cell i.e. it detonates. Likewise these medications may meddle with cell division so the cell quits developing and separating. Along these lines cytotoxic medications are fundamentally used to regard disease as a feature of a chemotherapy administration. Though it has likewise been utilized for regarding certain skin conditions, for example, psoriasis and rheumatoid joint inflammation. Cytotoxic medications have serious reactions as it slaughter malignancy cells yet additionally harms typical and sound cells. Cytotoxic medications advertise involves drugs with various particles having diverse system of activity and are utilized amid chemotherapy regimens. These medications comes in oral and additionally intravascular frame. They are dominatingly utilized as a part of leukemia and lymphomas and in conjunction with surgery, radiotherapy and immunotherapy to treat harmful tumors

Cytotoxic medications showcase is developing, this is credited to the rising worldwide predominance of different growths i.e. bosom, prostate, skin, blood, gastrointestinal tract, and lungs and so on in this manner expanding interest of cytotoxic medications for treating tumor is the essential factor boosting the income development of cytotoxic medications advertise over the conjecture time frame. Moreover, increment in the quantity of item dispatches and improvement of cutting edge restorative modalities are likewise driving the income development of cytotoxic medications showcase. Though factors, for example, developing pervasiveness of bone tumors, delicate tissue sarcomas and rheumatoid joint inflammation likewise add to the income development of cytotoxic medications showcase. Additionally, accessibility of cutting edge cytotoxic medications alongside rising medicinal services use and developing protection scope drives the cytotoxic medications advertise, hence giving tremendous chances to the medication producers inside this market. However extreme reactions identified with these medications and estimating of cytotoxic medications hampers the income development of the market. Cytotoxic Drugs showcase is relied upon to develop at a critical rate, over the figure time frame.

The global cytotoxic drugs market is segmented on the basis of drug type, route of administration, distribution channel and geography. On the basis of drug type, the global cytotoxic drugs market can be segmented into Alkylating Agents, Antimetabolites, Epipodophyllo Toxins, Vinca Alkaloids, Camptothecin Analogues, Taxanes, and Miscellaneous. On the basis of route of administration, the global cytotoxic drugs market can be segmented into Intravenous and Oral. By distribution channels, the global cytotoxic drugs market can be segmented into Retail Pharmacies, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. On the basis of geography, the global cytotoxic drugs market can be segmented into North America. Some of the companies in the cytotoxic drugs market are Roche Diagnostics, Eli Lilly and Company, Sanofi, Pfizer, Celgene Corporation, Amgen Inc., GlaxoSmithKline PLC, Novartis AG, Johnson and Johnson and Merck & Company among others.


Upcoming

Medical products are vital component of every veterinary, medical, and dental practice. There is an increased demand for medical supplies as large number of hospitals and outpatient facilities are increasingly adopting rigid infection prevention safety measures in order to meet firm standards. Some of the examples of medical supplies include conventional syringes with needles, blood glucose test strips, medical gloves, facemasks, prefilled syringes, isolation gowns, disposable contact lenses, procedure kits and trays, adult incontinence products, wound care products, surgical drapes, disposable medical catheters, and lancing devices. The medical disposable products are designed to decrease the discomfort and distress caused to the patients.

The global medical supplies market can be classified based on type, application, end user, and region. By type, the global medical supplies market is classified into diagnostic, dialysis, wound care, inhalation, infection control, infusion, intubation, PPE. Depending upon application, it is segmented into anesthesia, radiology, and sterilization. As per end-user, it is divided into hospitals, clinics, and nursing home.

The global medical supplies market is forecasted to grow at a rapid pace during the forecast period. Factors such as the rise in usage of medical supplies owing to increasing prevalence of diseases and disorders, presence of aging population and penalties for hospital acquired infection conditions are the major factors propelling the growth for global medical supplies market. Additionally, rise in the prevalence of incontinence problems is fuelling this market growth. However, the presence of substitute products as well as pressure of healthcare cost inhibition is the major factors hampering the growth for global medical supplies market.

The rising emphasis on prevention of infection in healthcare arena, usage of dry powder inhalers, blood glucose test strips, biological wound closures and intermittent urinary catheters would lead to the development of opportunity for global medical supplies market. The introduction of novel, higher and safety products and adoption of home healthcare products are the major trends in this medical supplies market.

Based on regions, the global medical supplies market is divided into North America, Europe, Asia-Pacific (APAC), Middle East & Africa (MEA), and Latin America. The North American region is anticipated to command the maximum market share and would lead the medical supplies market during the future period. The presence of a big geriatric population is major factor responsible for the large market share of this region. The Asia-Pacific region followed by the European nations is anticipated to showcase high growth rates in the future years in global disposable medical supplies market. Emerging economies such as China and India are expected to be the swiftly growing disposable medical supplies markets in Asia-Pacific region. The major factor propelling the growth of medical supplies market in emerging countries includes large patient pool and improving services pertaining to healthcare.

The major companies that provide medical supplies include Kimberly-Clark Corporation, B. Braun Melsungen AG, Becton Dickinson and Company, Johnson & Johnson, Bayer Healthcare AG, Roche Diagnostics Corporation and Abbott Diabetes Care Inc. among others.


© Copyright 2017-18 All rights reserved.